Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Insmed鈥檚 filings can feel like decoding a clinical study: dozens of pages on nebulizer technology, R&D burn, and FDA timelines hidden in dense legal text. If you have ever wondered, 鈥淲here can I find Insmed鈥檚 quarterly earnings report 10-Q filing?鈥� or needed real-time alerts on Insmed insider trading Form 4 transactions before the market reacts, you are not alone.
Stock Titan removes that friction. Our AI engine highlights trial-related milestones, breaks down cash runway assumptions, and tags every risk factor so you can understand Insmed SEC documents with AI in minutes, not hours. From the Insmed annual report 10-K simplified to each 8-K material events explained, we stream filings from EDGAR the moment they post and layer in plain-English summaries, key metrics, and historical comparisons.
Use cases include:
- Instant email or SMS alerts on Insmed Form 4 insider transactions real-time to monitor executive stock moves.
- Side-by-side Insmed earnings report filing analysis to track R&D expense versus pipeline progress across quarters.
- Quick look-ups of the latest Insmed proxy statement executive compensation without paging through appendices.
Every filing type is covered鈥�10-K, 10-Q, 8-K, S-3, DEF 14A鈥攃omplete with AI-powered summaries, red-flag detection, and searchable text. Whether you are modeling milestone payments or gauging launch readiness for ARIKAYCE, our platform surfaces the insights hidden in technical jargon. Save hours, spot trends early, and make confident decisions with comprehensive coverage of Insmed SEC filings explained simply.
Insmed Inc. (INSM) 鈥� Form 4 insider transaction dated 07/15/2025
Chairman & CEO William Lewis, acting through the Katie Procter Dynasty Trust, exercised 6,830 stock options at an exercise price of $10.85 and immediately sold the same 6,830 shares under a Rule 10b5-1 trading plan adopted on 09/12/2024. The shares were disposed of in three tranches at weighted-average prices of $101.71, $102.66 and $103.32, generating roughly $0.7 million in gross proceeds.
Following the transactions, Lewis鈥� total beneficial ownership equals 588,335 common shares (303,911 direct; 233,924 via the Dynasty Trust; 50,500 via the Family Legacy Trust). The option exercise did not change his overall share count, but the sales reduced the Dynasty Trust鈥檚 holdings by 2.8%. No derivative positions were opened or closed other than the exercised option, which now leaves 13,695 options outstanding for the Trust.
The sale size is modest relative to Lewis鈥� remaining stake and was pre-scheduled, limiting signaling value. Nevertheless, investors often view insider disposals, especially near 52-week highs (INSM traded >$100), as a potential sentiment check.
Insmed Inc. (INSM) Form 4 filing discloses two open-market sales by Chief Legal Officer Michael A. Smith.
- 07/11/2025: 748 common shares sold at $96.41 to satisfy tax-withholding on RSU vesting.
- 07/15/2025: 933 common shares sold at a $102.51 weighted-average price under a pre-arranged Rule 10b5-1 trading plan adopted 02/27/2025.
- Total shares disposed: 1,681, representing roughly 2.5 % of his pre-sale direct holdings.
- Post-sale direct ownership: 66,394 shares, including 357 acquired via the 2018 ESPP.
No derivative transactions were reported. Sales appear routine and transparent, suggesting limited immediate valuation impact for investors.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
